Skip to Content
Cancer Therapy Evaluation Program (CTEP)
Contact NExT
Show menu
Search this site
Last Updated: 12/14/21

Ellen Mintz, Ph.D., M.S.

Regulatory Affairs Specialist

Dr. Ellen Mintz started with the Regulatory Affairs Branch in October 2019 as an NCI Presidential Management Fellow and completed her rotations with both the Agreement Coordination Group and the Drug Regulatory group of the Branch. As an NCI Presidential Management Fellow, she also completed an external detail at HHS in the Office of the Assistant Secretary for Preparedness and Response. Dr. Mintz officially became a member of the Drug Regulatory Group in February 2021. She provides regulatory support and IND management for a complex portfolio of the investigational agents.

Dr. Mintz earned her Ph.D. in Experimental Pathology from the University of Virginia School of Medicine, where she developed and assessed tissue engineering based approaches for the treatment of skeletal muscle injuries. She also received a M.S. in Biological Sciences from California Polytechnic State University, San Luis Obispo. Her thesis focused on the role of the Wnt signaling pathway in stem cell reprogramming, supported in part by a research internship from the California Institute for Regenerative Medicine.

About the Branch Chief

Bhanu Ramineni, M.S., M.S. Bhanu Ramineni, M.S., M.S., became the Chief of the Regulatory Affairs Branch in October 2019. She joined the Drug Regulatory Group in the branch in 2010. She holds two Master's degrees: one in Environmental Sciences from Nagarjuna University, India, and a second one in Biochemistry and Molecular Biology with a specialization in Biotechnology from Georgetown University. Ms. Ramineni comes with significant experience in FDA Regulatory Affairs, as well as preclinical and clinical development of vaccines with a special focus in immunology. More…